Product Information

CAS No.	956104-40-8
Product Name	Apalutamide

Biological Targets

Associated Conditions

prostate cancer·prostate carcinoma·prostate adenocarcinoma·neoplasm·cancer·

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

The New England journal of medicine • Vol. 378, Issue 15 • 2018

PMID: 29420164 DOI: 10.1056/NEJMoa1715546

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.

European urology • Vol. 70, Issue 6 • 2016

PMID: 27160947 PMC: PMC5568792 DOI: 10.1016/j.eururo.2016.04.023

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.

Scientific reports • Vol. 5 • 2015

PMID: 26137992 PMC: PMC4490394 DOI: 10.1038/srep12007

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Vol. 31, Issue 28 • 2013

PMID: 24002508 PMC: PMC3782148 DOI: 10.1200/JCO.2013.50.1684

Apalutamide

CAS No.	956104-40-8
MDL No.	MFCD22380626
MF	C₂₁H₁₅F₄N₅O₂S
MW	477.40
InChI Key	HJBWBFZLDZWPHF-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	956104-40-8
Product Name	Apalutamide

Biological Targets

Associated Conditions

prostate cancer·prostate carcinoma·prostate adenocarcinoma·neoplasm·cancer·

* The information provided here is compiled from public sources and is for reference only.

Apalutamide

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Apalutamide

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Apalutamide

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

Similar Products

N-Desmethylapalutamide

4-(7-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro(3.4)octan-5-yl)-2-fluorobenzoic acid

Apalutamide

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

Similar Products

N-Desmethylapalutamide

4-(7-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro(3.4)octan-5-yl)-2-fluorobenzoic acid

Documentation